Literature DB >> 23857406

Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies.

Yoshihisa Kobayashi1, Yukinori Sakao, Simon Ito, Jangchul Park, Hiroaki Kuroda, Noriaki Sakakura, Noriyasu Usami, Tetsuya Mitsudomi, Yasushi Yatabe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23857406     DOI： 10.1097/JTO.0b013e318293d96f

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  14 in total

1.  Clinicopathological factors influenced the prognosis of surgically resected pulmonary pleomorphic carcinoma.

Authors:  Katsuhiro Okuda; Risa Oda; Ayumi Suzuki; Tadashi Sakane; Osamu Kawano; Hiroshi Haneda; Satoru Moriyama; Ryoichi Nakanishi
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

2.  Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases.

Authors:  Simone Bsp Terra; Jin S Jang; Lintao Bi; Benjamin R Kipp; Jin Jen; Eunhee S Yi; Jennifer M Boland
Journal:  Mod Pathol       Date:  2016-05-13       Impact factor: 7.842

3.  Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma.

Authors:  Xianjin Xie; Xudong Chen; Ningning Luo; Yingxue Qi; Mengmeng Li; Xiaoya Feng
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-15       Impact factor: 4.322

Review 4.  Crizotinib resistance: implications for therapeutic strategies.

Authors:  I Dagogo-Jack; A T Shaw
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

Review 5.  Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.

Authors:  Bin-Chi Liao; Chia-Chi Lin; Jin-Yuan Shih; James Chih-Hsin Yang
Journal:  Ther Adv Med Oncol       Date:  2015-09       Impact factor: 8.168

6.  Histologic transformation of non-small-cell lung cancer in brain metastases.

Authors:  Meng Jiang; Xiaolong Zhu; Xiao Han; Haiyan Jing; Tao Han; Qiang Li; Xiao Ding
Journal:  Int J Clin Oncol       Date:  2018-11-16       Impact factor: 3.402

7.  Pulmonary sarcomatoid carcinoma: University of Cincinnati experience.

Authors:  Nagla Abdel Karim; James Schuster; Ihab Eldessouki; Ola Gaber; Tariq Namad; Jiang Wang; Changchun Xie; John C Morris
Journal:  Oncotarget       Date:  2017-12-18

8.  Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors.

Authors:  Jongmin Sim; Hyunjin Kim; Jiyeon Hyeon; Yoon La Choi; Joungho Han
Journal:  J Korean Med Sci       Date:  2018-04-09       Impact factor: 2.153

9.  Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.

Authors:  Akihiro Kogita; Yosuke Togashi; Hidetoshi Hayashi; Shunsuke Sogabe; Masato Terashima; Marco A De Velasco; Kazuko Sakai; Yoshihiko Fujita; Shuta Tomida; Yoshifumi Takeyama; Kiyotaka Okuno; Kazuhiko Nakagawa; Kazuto Nishio
Journal:  Int J Oncol       Date:  2014-08-01       Impact factor: 5.650

10.  High-fidelity of non-small cell lung cancer xenograft models derived from bronchoscopy-guided biopsies.

Authors:  Shuai Fu; Jun Zhao; Hua Bai; Jianchun Duan; Zhijie Wang; Tongtong An; Jie Wang
Journal:  Thorac Cancer       Date:  2015-09-08       Impact factor: 3.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.